Avacta Group (LON:AVCT) Issues Earnings Results

Avacta Group (LON:AVCT) posted its quarterly earnings data on Tuesday. The biotechnology company reported GBX (9.27) EPS for the quarter, Digital Look Earnings reports. The company had revenue of GBX 11 million for the quarter. Avacta Group had a negative net margin of 30,398.21% and a negative return on equity of 361.23%.

Avacta Group Stock Down 0.9%

Shares of LON:AVCT opened at GBX 81.30 on Wednesday. The stock has a market capitalization of £368.70 million, a price-to-earnings ratio of -4.63 and a beta of 1.12. Avacta Group has a 1-year low of GBX 26 and a 1-year high of GBX 92. The company’s fifty day moving average is GBX 72.88 and its two-hundred day moving average is GBX 67.95. The company has a debt-to-equity ratio of 14,168.75, a quick ratio of 4.96 and a current ratio of 0.79.

About Avacta Group

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics.
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.

Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).